Company Overview
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical entity dedicated to developing gene and cell therapies that utilize precision technology to target diseases within immuno-oncology, autoimmune disorders, and infectious diseases. The company functions through two distinct segments, Biopharmaceuticals and Exemplar, positioning itself within the broader Healthcare sector under the specific industry of Biotechnology. In terms of scale, Precigen reports a market capitalization of $1.17B, generates annual revenue of $6.31M, and employs 143 individuals to support its research and development activities. The combination of a $1.17B market cap and $6.31M in revenue indicates that the company is a mid-sized public entity with significant valuation relative to its current sales volume, a common characteristic for early-stage biotechnology firms where future potential is priced in rather than realized through current cash flows.
Financial Health
The company reports a revenue of $6.31M for the trailing twelve months, yet it simultaneously records a net income of $-425,865,984 and an EBITDA of $-104,948,000. This substantial gap between the $6.31M revenue and the negative net income reveals a cost structure where operating expenses and research costs far exceed current sales, a typical scenario for clinical-stage companies still in the development phase. The free cash flow stands at $-47,835,752, which indicates that the company is consuming cash to fund its operations and pipeline advancement rather than generating surplus liquidity for debt repayment or dividends. Analyzing the three margins shows a gross margin of 0.0%, an operating margin of -1180.0%, and a profit margin of 0.0%, each figure reflecting the intense capital expenditure required to advance therapies before commercial viability is achieved. Regarding balance sheet leverage, the company holds $121.14M in cash against $98.19M in debt, supported by a debt-to-equity ratio of 234.53, suggesting a leveraged position that relies heavily on its cash reserves to service obligations. The current ratio is 4.04, indicating a robust short-term liquidity position where current assets are more than four times current liabilities, providing a buffer for operational needs. Finally, the return on equity is -507.7% and the return on assets is -52.8%, metrics that reveal that management has not yet achieved profitability, with negative returns reflecting the dilution of equity and asset base by significant net losses.
Valuation Assessment
The valuation metrics show a P/E Ratio (TTM) of N/A due to losses, while the forward P/E is -15.05, implying that the market prices the stock based on future expectations of earnings recovery rather than current performance. The price-to-book ratio is 28.05, which indicates a significant market premium over the company's book value, suggesting investors are willing to pay a high multiple for the potential of its intellectual property and pipeline. Alternative valuation metrics include a price-to-sales ratio of 185.63 and an EV/EBITDA of -10.84, which suggest that the stock is valued almost entirely on projected future success rather than historical financial performance. The 52-week high is $5.47 and the 52-week low is $1.11, and without a specific current price provided in the source data, the valuation range suggests extreme volatility typical of biotech stocks trading near their lows or highs. The beta is 1.17, meaning the stock price exhibits higher volatility relative to the broader market, moving 17% more than the market index during periods of fluctuation.
Growth & Income
Precigen reports a revenue growth of 206.6% year-over-year, while earnings growth is N/A due to the absence of reported net income. This disparity indicates that while top-line sales are expanding rapidly, the company is not yet profitable enough to drive earnings growth, implying that profitability remains the primary hurdle for future financial improvement. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests all available earnings and cash reserves directly into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by explosive top-line expansion in revenue coupled with a complete lack of current income distribution, reflecting the strategic focus on long-term asset building rather than short-term shareholder returns.